OpenAlex konusu

Lung Cancer Research Studies

Bu sayfa OpenAlex konu etiketine göre çalışmaları ve o konuda görünen akademisyenleri listeler. YÖKSİS temel alan / yan dal değildir.

OpenAlex 2.146 eser 45 yazar konusu

Çalışmalar

2.146 eser

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy Naive Patients With Advanced Stage Non Small Cell Lung Cancer 2008
YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 100.0%
PURPOSE: Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non-small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS: This noninferiority, phase III, randomized study compared the overall…
- TUNCAY GÖKSEL
title Alectinib versus Crizotinib in Untreated iALK/i -Positive Non–Small-Cell Lung Cancer/title 2017
YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 100.0%
BACKGROUND: Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lung cancer (NSCLC). We investigated alectinib as compared with crizotinib in patients with previously untreated, advance…
- AHMET DEMİRKAZIK
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial 2019
YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 100.0%
Özet henüz yok.
- AHMET ALACACIOĞLU
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial 2019
YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 100.0%
Özet henüz yok.
- AHMET DEMİRKAZIK
- TUNCAY GÖKSEL
Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial 2019
YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 100.0%
Özet henüz yok.
- MUSTAFA ÖZGÜROĞLU
Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study 2011
YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.9%
PURPOSE: This European Organisation for Research and Treatment of Cancer phase III trial assesses whether adjuvant whole-brain radiotherapy (WBRT) increases the duration of functional independence after surgery or radiosurgery of brain metastases. PATIENTS AND METHODS: Patients with one to three brain metastases of so…
- MEHMET UFUK ABACIOĞLU
Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer 1991
OpenAlex üst %1 OpenAlex 99.9%
BACKGROUND: Neutropenia and infection are major dose-limiting side effects of chemotherapy. Previous studies have suggested that recombinant methionyl granulocyte colony-stimulating factor (G-CSF) can reduce chemotherapy-related neutropenia in patients with cancer. We conducted a randomized clinical trial to test this…
Ramucirumab plus docetaxel versus placebo plus docetaxel for second line treatment of stage IV non small cell lung cancer after disease progression on platinum based therapy REVEL a multicentre double blind randomised phase 3 trial 2014
YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 100.0%
Özet henüz yok.
- TUNCAY GÖKSEL
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study 2020
OpenAlex üst %1 OpenAlex 99.8%
PURPOSE Pembrolizumab monotherapy has shown antitumor activity in patients with small-cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study compared pembrolizumab plus etoposide and platinum (EP) with placebo plus EP for patients with previously untreated extensive-stage (ES) SCLC. METHODS…
Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy 2006
YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %10 OpenAlex 98.4%
Özet henüz yok.
- ALİ DOĞAN
Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy 2006
YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %10 OpenAlex 98.4%
Özet henüz yok.
- ABDURRAHMAN OĞUZHAN
Durvalumab, with or without tremelimumab, plus platinum\u2013etoposide versus platinum\u2013etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial 2021
YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.7%
Özet henüz yok.
- AHMET DEMİRKAZIK

Akademisyenler

45 akademisyen